mTOR-Inhibitors-Modulators-MCE

1、 HYPERLINK https:/www.MedChemE/Targets/mTOR.html mTORMammalian target of RapamycinmTOR (mammalian target of Rapamycin) is a protein that in humans is encoded by the mTOR gene. mTOR is a serine/threonineprotein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, prote

2、in synthesis, and transcription. mTORbelongs to the phosphatidylinositol 3-kinase-related kinase protein family. mTOR integrates the input from upstream pathways,including growth factors and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway isdysregulated i

3、n human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR byassociating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding(FRB) domain of mTOR, inhibiting its activity.www.MedChemE 12 Tel: 60

4、9-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/Targets/mTOR.html mTOR HYPERLINK https:/www.MedChemE/Targets/mTOR.html HYPERLINK https:/www.MedChemE/Targets/mTOR.html Inhibitors, HYPERLINK https:/www.MedChemE/Targets/mTOR.html HYPERLINK https:/www.MedChemE/Targets/mTO

5、R.html Antagonists, HYPERLINK https:/www.MedChemE/Targets/mTOR.html HYPERLINK https:/www.MedChemE/Targets/mTOR.html Activators HYPERLINK https:/www.MedChemE/Targets/mTOR.html HYPERLINK https:/www.MedChemE/Targets/mTOR.html & HYPERLINK https:/www.MedChemE/Targets/mTOR.html HYPERLINK https:/www.MedChe

6、mE/Targets/mTOR.html Modulators HYPERLINK https:/www.MedChemE/usnic-acid.html (+)-Usnic HYPERLINK https:/www.MedChemE/usnic-acid.html HYPERLINK https:/www.MedChemE/usnic-acid.html acid HYPERLINK https:/www.MedChemE/usnic-acid.html HYPERLINK https:/www.MedChemE/32-carbonyl-rmc-5552.html (32-Carbonyl)

7、-RMC-5552Cat. No.: HY-N0656A Cat. No.: HY-134903(+)-Usnic acid is isolated from isolated fromlichens, binds at the ATP-binding pocket ofmTOR, and inhibits mTORC1/2 activity.(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor.(32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2substrate (p-P70S6K-(T389),

8、p-4E-BP1-(T37/36), ANDp-AKT1/2/3-(S473) phosphorylation with pIC s of50 9, 9 and between 8 and 9, respectively(patent WO2019212990A1, example 2).Purity: 99.0%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 100 mgPurity: 95.04%Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mg, 25

9、mg HYPERLINK https:/www.MedChemE/25-r-s-ruscogenin.html 25(R,S)-Ruscogenin HYPERLINK https:/www.MedChemE/25-r-s-ruscogenin.html HYPERLINK https:/www.MedChemE/3BDO.html 3BDOCat. No.: HY-N5136 Cat. No.: HY-U00434Ruscogenin suppresses HCC metastasis by reducingthe expression of MMP-2, MMP-9, uPA, VEGF

10、andHIF-1 via regulating the PI3K/Akt/mTORsignaling pathway. And Ruscogenin alleviatesLPS-induced pulmonary endothelial cell apoptosisby su.3BDO is a new mTOR activator which can alsoinhibit autophagy.Purity: 99.84%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.91%Cl

11、inical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg HYPERLINK https:/www.MedChemE/8-aminoadenosine.html 8-Aminoadenosine(8-NH2-Ado) Cat. No.: HY-125927 HYPERLINK https:/www.MedChemE/gdc-0980.html Apitolisib(GDC-0980; GNE 390; RG 7422) Cat. No.: HY-132468-Aminoadenosine (8-NH2-Ad

12、o), a RNA-directednucleoside analogue, reduces cellular ATP levelsand inhibits mRNA synthesis. 8-Aminoadenosineblocks Akt/mTOR signaling and inducesautophagy and apoptosis in a p53-independentmanner. 8-Aminoadenosine has antitumor activity.Apitolisib (GDC-0980; GNE 390; RG 7422) is aselective, poten

13、t, orally bioavailable Class I PI3kinase and mTOR kinase (TORC1/2) inhibitorwith IC s of 5 nM/27 nM/7 nM/14 nM for50PI3K/PI3K/PI3K/PI3K, and with a K ofi17 nM for mTOR.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.26%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg,

14、50 mg, 100 mg HYPERLINK https:/www.MedChemE/arnicolide-d.html Arnicolide HYPERLINK https:/www.MedChemE/arnicolide-d.html HYPERLINK https:/www.MedChemE/arnicolide-d.html D HYPERLINK https:/www.MedChemE/arnicolide-d.html HYPERLINK https:/www.MedChemE/AZD-8055.html AZD-8055Cat. No.: HY-N6843 Cat. No.:

15、HY-10422Arnicolide D is a sesquiterpene lactone isolatedfrom Centipeda minima. Arnicolide D modulatesthe cell cycle, activates the caspase signalingpathway and inhibits the PI3K/AKT/mTOR andSTAT3 signaling pathways.AZD-8055 is a potent, selective, and orallybioavailable ATP-competitive mTOR kinasein

16、hibitor with an IC of 0.8 nM. AZD-805550inhibits both mTORC1 and mTORC2.Purity: 99.20%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.60%Clinical Data: Phase 1Size: 10 mM 1 mL, 10 mg, 50 mg, 100 mg, 200 mg HYPERLINK https:/www.MedChemE/BGT226.html BGT226 HYPERLINK https:/www.MedChem

17、E/BGT226.html HYPERLINK https:/www.MedChemE/nvp-bgt226.html BGT226 HYPERLINK https:/www.MedChemE/nvp-bgt226.html HYPERLINK https:/www.MedChemE/nvp-bgt226.html maleate(NVP-BGT226) Cat. No.: HY-13334A (NVP-BGT226 maleate) Cat. No.: HY-13334BGT226 (NVP-BGT226) is a PI3K (with IC s of 4 nM,5063 nM and 3

18、8 nM for PI3K, PI3K and PI3K)/mTORdual inhibitor which displays potentgrowth-inhibitory activity against human head andneck cancer cells.BGT226 (NVP-BGT226 maleate) is a PI3K (with IC s50of 4 nM, 63 nM and 38 nM for PI3K, PI3K and PI3K)/mTOR dual inhibitor which displays potentgrowth-inhibitory acti

19、vity against human head andneck cancer cells.Purity: 98%Clinical Data: Phase 2Size: 1 mg, 5 mgPurity: 99.73%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/PQR309.html Bimiralisib(PQR309) Cat. No.: HY-12868 HYPERLINK https:/www.MedChemE/

20、Cbz-B3A.html Cbz-B3ACat. No.: HY-114267Bimiralisib (PQR309) is a potent, brain-penetrant,orally bioavailable, pan-class I PI3K/mTORinhibitor with IC s of 33 nM, 451 nM, 661 nM, 70850nM and 89 nM for PI3K, PI3K, PI3K, PI3K andmTOR, respectively. Bimiralisib is an mTORC1and mTORC2 inhibitor.Cbz-B3A is

21、 a potent and selective inhibitor ofmTORC1 signaling that appear to bind toubiquilins 1, 2, and 4, and Cbz-B3A inhibits thephosphorylation of eIF4E-binding protein 1(4EBP1).Purity: 98.74%Clinical Data: Phase 2Size: 10 mM 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98.0%Clinical Data: No Developmen

22、t ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/CC-115.html CC-115 HYPERLINK https:/www.MedChemE/CC-115.html HYPERLINK https:/www.MedChemE/CC-115-hydrochloride.html CC-115 HYPERLINK https:/www.MedChemE/CC-115-hydrochloride.html HYPERLINK https:/www.MedChemE/CC-115-hydrochloride.html hydroch

23、lorideCat. No.: HY-16962 Cat. No.: HY-16962ACC-115 is a potent and dual DNA-PK and mTORkinase inhibitor with IC s of 13 nM and 21 nM,50respectively. CC-115 blocks both mTORC1 andmTORC2 signaling.CC-115 hydrochloride is a potent and dual DNA-PKand mTOR kinase inhibitor with IC s of 13 nM50and 21 nM,

24、respectively. CC-115 blocks bothmTORC1 and mTORC2 signaling.Purity: 98.04%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 98.23%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg HYPERLINK https:/www.MedChemE/cc214-2.html CC214-2 HYPERLINK https:/www.MedChemE/cc214-2.html H

25、YPERLINK https:/www.MedChemE/cyclovirobuxine-d.html Cyclovirobuxine HYPERLINK https:/www.MedChemE/cyclovirobuxine-d.html HYPERLINK https:/www.MedChemE/cyclovirobuxine-d.html DCat. No.: HY-145931 Cat. No.: HY-N0107CC214-2 is a potent and dual inhibitor ofmTORC1/mTORC2. Mycobacterium tuberculosismodul

26、ates mammalian target of rapamycin (mTOR)signaling to impede autophagy. CC214-2 has thepotential to shorten the duration of TB.Cyclovirobuxine D (CVB-D) is the main activecomponent of the traditional Chinese medicine Buxusmicrophylla. Cyclovirobuxine D inducesautophagy and attenuates the phosphoryla

27、tion ofAkt and mTOR.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 95.0%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 20 mg HYPERLINK https:/www.MedChemE/CZ415.html CZ415 HYPERLINK https:/www.MedChemE/CZ415.html HYPERLINK https:/www.MedChemE/d-hydroxy

28、glutaric-acid.html D-Hydroxyglutaric HYPERLINK https:/www.MedChemE/d-hydroxyglutaric-acid.html HYPERLINK https:/www.MedChemE/d-hydroxyglutaric-acid.html acid HYPERLINK https:/www.MedChemE/d-hydroxyglutaric-acid.html (R)-2-Hydroxyglutarate;Cat. No.: HY-100222(R)-2-Hydroxyglutaric acid; ) Cat. No.: HY

29、-113038CZ415 is a potent and highly selective mTORinhibitor with a pIC of 8.07. CZ415 inhibits50mTORC1 and mTORC2 protein complex.D-Hydroxyglutaric acid (R)-2-Hydroxyglutarate)is the principal metabolite accumulating inneurometabolic disease D-2-hydroxyglutaricaciduria.Purity: 98.74%Clinical Data: N

30、o Development ReportedSize: 10 mM 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg HYPERLINK https:/www.MedChemE/D-alpha-Hydroxyglutaric-acid-disodium-salt.html D-Hydroxyglutaric HYPERLINK https:/www.MedChemE/D-alpha-Hydroxyglutaric-acid

31、-disodium-salt.html HYPERLINK https:/www.MedChemE/D-alpha-Hydroxyglutaric-acid-disodium-salt.html acid HYPERLINK https:/www.MedChemE/D-alpha-Hydroxyglutaric-acid-disodium-salt.html HYPERLINK https:/www.MedChemE/D-alpha-Hydroxyglutaric-acid-disodium-salt.html disodium HYPERLINK https:/www.MedChemE/D-

32、alpha-Hydroxyglutaric-acid-disodium-salt.html HYPERLINK https:/www.MedChemE/BEZ235.html Dactolisib(Disodium (R)-2-hydroxyglutarate) Cat. No.: HY-100542 (BEZ235; NVP-BEZ235) Cat. No.: HY-50673D-Hydroxyglutaric acid disodium (Disodium(R)-2-hydroxyglutarate) is the principalmetabolite accumulating in n

33、eurometabolic diseaseD-2-hydroxyglutaric aciduria.Dactolisib (BEZ235) is an orally active and dualpan-class I PI3K and mTOR kinase inhibitor withIC s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for50p110/p110/p110/p110 and mTOR,respectively. Dactolisib (BEZ235) inhibits bothmTORC1 and mTORC2.Purity: 98.0%C

34、linical Data: No Development ReportedSize: 10 mM 1 mL, 10 mg, 25 mg, 50 mg, 100 mgPurity: 99.94%Clinical Data: Phase 3Size: 50 mg, 100 mg, 200 mg, 500 mg4 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/BEZ235-Tosylate.html Dactolisib HYPERLINK https:/www.MedCh

35、emE/BEZ235-Tosylate.html HYPERLINK https:/www.MedChemE/BEZ235-Tosylate.html Tosylate(BEZ235 Tosylate; NVP-BEZ 235 Tosylate) Cat. No.: HY-15174 HYPERLINK https:/www.MedChemE/desmethyl-vs-5584.html Desmethyl-VS-5584(Desmethyl-SB2343) Cat. No.: HY-101776Dactolisib Tosylate (BEZ235 Tosylate) is a dualPI

36、3K and mTOR kinase inhibitor with IC values50of 4, 75, 7, 5 nM for PI3K, , , ,respectively. Dactolisib Tosylate (BEZ235Tosylate) inhibits mTORC1 and mTORC2.Desmethyl-VS-5584 is a dimethyl analog of VS-5584which is an potent and selective mTOR/PI3K dualinhibitor with pyrido 2,3-d pyrimidinestructure.

37、Purity: 99.88%Clinical Data: Phase 3Size: 10 mM 1 mL, 50 mg, 100 mg, 200 mg, 500 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dihydroevocarpine.html DihydroevocarpineCat. No.: HY-N2517 HYPERLINK https:/www.MedChemE/Dihydromyricetin.html Dihydromyr

38、icetin(Ampelopsin; Ampeloptin) Cat. No.: HY-N0112Dihydroevocarpine induces cytotoxicity in acutemyeloid leukemia via suppressing the mTORC1/2activity.Dihydromyricetin is a potent inhibitor with anIC50 of 48 M on dihydropyrimidinase.Dihydromyricetin can activate autophagy throughinhibiting mTOR signa

39、ling. Dihydromyricetinsuppresses the formation of mTOR complexes(mTORC1/2).Purity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mgPurity: 99.79%Clinical Data: Phase 2Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/ds-7423.html DS-7423 HYPERLINK https:/www

40、.MedChemE/ds-7423.html HYPERLINK https:/www.MedChemE/etp-45658.html ETP-45658Cat. No.: HY-124036 Cat. No.: HY-110109DS-7423 is a dual PI3K and mTOR inhibitor, withIC values of 15.6 nM, 34.9 nM for PI3K and50mTOR, respectively. DS-7423 possesses anti-tumoractivity.ETP-45658 is a potent PI3K inhibitor

41、, with IC s of5022.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3K,PI3K, PI3K and PI3K, respectively. ETP-45658 alsocan inhibit DNA-PK (IC =70.6 nM) and50 mTOR(IC =152.0 nM). ETP-45658 can be used for the50research of cancer.Purity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50

42、 mg, 100 mgPurity: 98.05%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/etp-46464.html ETP-46464 HYPERLINK https:/www.MedChemE/etp-46464.html HYPERLINK https:/www.MedChemE/Everolimus.html EverolimusCat. No.: HY-15521(RAD001; SDZ-RAD) Cat. No.: HY

43、-10218ETP-46464 is an effective mTOR and ATRinhibitor with IC s of 0.6 and 14 nM,50respectively.Everolimus (RAD001) is a Rapamycin derivative anda potent, selective and orally active mTOR1inhibitor. Everolimus binds to FKBP-12 togenerate an immunosuppressive complex. Everolimusinhibits tumor cells p

44、roliferation and inducescell apoptosis and autophagy.Purity: 98.01%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 99.74%Clinical Data: LaunchedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/everolimus-d4.html Everolimus-d4 HYPERL

45、INK https:/www.MedChemE/everolimus-d4.html HYPERLINK https:/www.MedChemE/FT-1518.html FT-1518(RAD001-d4; SDZ-RAD-d4) Cat. No.: HY-10218SCat. No.: HY-107363Everolimus-d4 (RAD001-d4) is the deuterium labeledEverolimus. Everolimus (RAD001) is a Rapamycinderivative and a potent, selective and orallyacti

46、ve mTOR1 inhibitor. Everolimus binds toFKBP-12 to generate an immunosuppressive complex.FT-1518 is a new generation selective, potent andoral bioavailable mTORC1 and mTORC2inhibitor, and exhibits antitumor activity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 10 mgPurity: 98%Clinical

47、 Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mgwww.MedChemE 5 HYPERLINK https:/www.MedChemE/gdc-0349.html GDC-0349Cat. No.: HY-15248 HYPERLINK https:/www.MedChemE/PKI-587.html Gedatolisib(PKI-587; PF-05212384) Cat. No.: HY-10681GDC-0349 is a potent and selective ATP-competitive

48、mTOR inhibitor with a K of 3.8 nM. GDC-0349iinhibits of both mTORC1 and mTORC2complexes.Gedatolisib (PKI-587) is a highly potent dualinhibitor of PI3K, PI3K, and mTOR with IC s of500.4 nM, 5.4 nM and 1.6 nM, respectively.Gedatolisib is equally effective in both complexesof mTOR, mTORC1 and mTORC2.Pu

49、rity: 98.42%Clinical Data: Phase 1Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mgPurity: 99.68%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/GNE-317.html GNE-317 HYPERLINK https:/www.MedChemE/GNE-317.html HYPERLINK https:/www.MedChemE/GNE-477.html GNE-477C

50、at. No.: HY-12763 Cat. No.: HY-11042GNE-317 is a PI3K/mTOR inhibitor, is able tocross the blood-brain barrier (BBB).GNE-477 is a potent and efficacious dual PI3K(IC =4 nM)/ ( =21 nM) inhibitor.50 mTOR KiPurity: 99.31%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgP

51、urity: 98.70%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg HYPERLINK https:/www.MedChemE/gne-490.html GNE-490 HYPERLINK https:/www.MedChemE/gne-490.html HYPERLINK https:/www.MedChemE/GNE-493.html GNE-493Cat. No.: HY-10812 Cat. No.: HY-10811GNE-490, a (thieno

52、pyrimidin-2-yl)aminopyrimidine,is a potent pan-PI3K inhibitor with IC s of 3.550nM, 25 nM, 5.2 nM, 15 nM for PI3K, PI3K,PI3K and PI3K, respectively. GNE-490 has 200fold selectivity for mTOR (IC =750 nM).50GNE-493 is a potent, selective, and orallyavailable dual pan-PI3-kinase/mTOR inhibitorwith IC s

53、 of 3.4 nM, 12 nM, 16 nM, 16 nM and 3250nM for PI3K, PI3K, PI3K, PI3K and mTOR.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.33%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg HYPERLINK https:/www.MedChemE/GSK1059615.html GSK1059615 HYPERLINK https:/

54、www.MedChemE/GSK1059615.html HYPERLINK https:/www.MedChemE/HDACs-mTOR_Inhibitor_1.html HDACs/mTOR HYPERLINK https:/www.MedChemE/HDACs-mTOR_Inhibitor_1.html HYPERLINK https:/www.MedChemE/HDACs-mTOR_Inhibitor_1.html Inhibitor HYPERLINK https:/www.MedChemE/HDACs-mTOR_Inhibitor_1.html HYPERLINK https:/w

55、ww.MedChemE/HDACs-mTOR_Inhibitor_1.html 1Cat. No.: HY-12036 Cat. No.: HY-114414GSK1059615 is a dual inhibitor of PI3K/(reversible) and mTOR with IC of 0.4 nM/0.650nM/2 nM/5 nM and 12 nM, respectively.HDACs/mTOR Inhibitor 1 is a dual HistoneDeacetylases (HDACs) and mammalian target ofRapamycin (mTOR)

56、 target inhibitor for treatinghematologic malignancies, with IC s of 0.19 nM,501.8 nM, 1.2 nM and 500 nM for HDAC1, HDAC6,mTOR and PI3K, respectively.Purity: 99.0%Clinical Data: Phase 1Size: 10 mM 1 mL, 5 mg, 10 mg, 50 mg, 100 mgPurity: 98.21%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5

57、 mg, 10 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/hederacolchiside-a1.html Hederacolchiside HYPERLINK https:/www.MedChemE/hederacolchiside-a1.html HYPERLINK https:/www.MedChemE/hederacolchiside-a1.html A1 HYPERLINK https:/www.MedChemE/hederacolchiside-a1.html HYPERLINK https:/www.MedChemE/hsmg

58、-1-inhibitor-11e.html hSMG-1 HYPERLINK https:/www.MedChemE/hsmg-1-inhibitor-11e.html HYPERLINK https:/www.MedChemE/hsmg-1-inhibitor-11e.html inhibitor HYPERLINK https:/www.MedChemE/hsmg-1-inhibitor-11e.html HYPERLINK https:/www.MedChemE/hsmg-1-inhibitor-11e.html 11eCat. No.: HY-N6950 Cat. No.: HY-12

59、4760Hederacolchiside A1, isolated from Pulsatillachinensis, suppresses proliferation of tumor cellsby inducing apoptosis through modulatingPI3K/Akt/mTOR signaling pathway.hSMG-1 inhibitor 11e is a potent and selectivehSMG-1 kinase inhibitor with an IC of 900-foldselectivity over mTOR (IC of 45 nM),

60、PI3K/50(IC s of 61 nM and 92 nM) and CDK1/CDK2 (IC s of50 5032 M and 7.1 M).Purity: 99.69%Clinical Data: No Development ReportedSize: 5 mg, 10 mgPurity: 99.18%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg6 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMe